Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Samsung Bioepis Sees Success With Soliris Biosimilar

SB12 Eculizumab Candidate Demonstrates Equivalence In Phase III Trial

Executive Summary

Samsung Bioepis has reported positive Phase III data for its SB12 proposed eculizumab biosimilar to Soliris, with the product showing equivalence in efficacy, safety, PK, PD and immunogenicity.

You may also be interested in...



Samsung Bioepis Celebrates Soliris Success

Samsung Bioepis has revealed positive Phase I trial results for its SB12 proposed eculizumab biosimilar rival to Soliris.

Samsung Bioepis Moves Forward With Soliris Rival

Samsung Bioepis has confirmed completion of its Phase III trial for a proposed biosimilar to Soliris, putting it ahead of rival developer Amgen which has negotiated a date-certain US launch.

Ultomiris FDA Approval Gives Soliris Biosimilars Bigger Hurdle

Alexion Pharmaceuticals’ Soliris (eculizumab) blockbuster represents a significant opportunity for biosimilar sponsors around the globe. Ahead of anticipated US competition in 2025, the originator has added a new formulation for next-generation product Ultomiris (ravulizumab-cwvz).

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151950

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel